Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of abaloparatide in postmenopausal osteoporosis
jRCT2080222331Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abaloparatide in postmenopausal osteoporosis (3 arms), sponsored by Teijin Pharma. Started Dec 2013; status: completed.
02
Drugs
abaloparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on jRCT2080222331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222331.